Recently published research from GlobalData, "ImmunoCellular Therapeutics, Ltd. (IMUC) - Product Pipeline Analysis", is now available at Fast Market Research

Boston, MA -- (SBWire) -- 06/14/2012 --ImmunoCellular Therapeutics, Ltd. (ImmunoCellular) is a clinical-stage biotechnology company. It undertakes the development of immune-based therapies to treat various types of cancers. The product pipeline of the company include active immunotherapies and patented monoclonal antibodies. The company's product candidate portfolio includes peptide based vaccine to target cancer stem cells; cellular immunotherapies targeting cancer antigens, cancer stem cell antigens; and monoclonal antibodies to diagnose and treat several different cancers including glioblastoma multiforme (GBM), small-cell lung cancer, pancreatic cancer and ovarian cancer.

View Full Report Details and Table of Contents

This report is a source for data, analysis and actionable intelligence on the ImmunoCellular Therapeutics, Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Get this Report

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Medical Devices research reports at Fast Market Research

You may also be interested in these related reports:

- BioMimetic Therapeutics, Inc. (BMTI) - Product Pipeline Analysis
- Anika Therapeutics, Inc. (ANIK) - Product Pipeline Analysis
- Cytori Therapeutics, Inc. (XMP) - Product Pipeline Analysis
- Cardium Therapeutics, Inc. (CXM) - Product Pipeline Analysis
- ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and Strategic SWOT Analysis Review
- ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - H2 2011
- Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development
- Pancreatic Cancer - Pipeline Review, Q2 2011
- Echo Therapeutics, Inc. (ECTE) - Product Pipeline Analysis
- GUIDED THERAPEUTICS, INC. (GTHP) - Product Pipeline Analysis